Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary transthyretin amyloidosis market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Hereditary Transthyretin Amyloidosis Market expected to reach by 2030?
The market size for hereditary transthyretin amyloidosis has demonstrated robust expansion in recent years. This market is forecast to increase from $1.49 billion in 2025 to $1.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The expansion observed historically can be attributed to heightened clinical recognition of attr amyloidosis, the availability of tafamidis therapy, the proliferation of specialized neurology and cardiology centers, enhancements in genetic testing for ttr mutations, and the growth of patient registry programs.
The hereditary transthyretin amyloidosis market is anticipated to experience robust expansion over the coming years, with projections indicating it will reach $2.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.9%. This upward trajectory is attributable to various factors, such as the increasing availability of next-generation gene therapies, heightened investment in rare disease research, the expanding adoption of precision medicine approaches, the rising development of crispr-based treatments, and advancements in technologies for monitoring disease outcomes. Furthermore, key developments expected in this timeframe include the wider acceptance of gene silencing therapies, a surge in the application of rnAI-based treatments, a heightened emphasis on early cardiac and neurological diagnosis, the broadening of oral therapeutic options, and the enhancement of long-term disease management strategies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
What Drivers Are Driving Adoption Within The Hereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosis market is expected to expand in the future, propelled by the growing number of older adults. This demographic includes individuals aged 65 and older, often requiring specialized healthcare and assistance due to the aging process. The increase in the geriatric population stems from longer life expectancies, which are themselves a result of advancements in healthcare and improvements in living conditions. Hereditary transthyretin amyloidosis (hATTR) significantly impacts older individuals by causing progressive neuropathy and cardiomyopathy, leading to increased rates of illness in this age group. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the US population aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, indicating a 47% increase. Therefore, the expanding geriatric population is a key factor driving the growth of the hereditary transthyretin amyloidosis market.
What Segments Are Included Within The Hereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Experimental Oral Therapies
2) By Subcutaneous Injection: Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Which Market Trends Are Opening Growth Opportunities In The Hereditary Transthyretin Amyloidosis Market?
Leading companies in the hereditary transthyretin amyloidosis market are actively developing novel treatments, including RNAi therapeutics, specifically designed to target and diminish the generation of transthyretin (TTR) protein. RNAi therapeutics constitute a category of drugs that leverage RNA interference technology to silence particular genes, thereby lessening the production of proteins that cause disease. As an illustration, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, filed a supplemental new drug application (sNDA) with the US FDA for Vutrisiran (AMVUTTRA) intended for the treatment of transthyretin amyloidosis with cardiomyopathy. This submission emphasizes its innovative RNAi therapeutic strategy, conceived to target and decrease transthyretin (TTR) protein, which is a pivotal element in the disease’s progression. The subcutaneous delivery of Vutrisiran offers a more convenient and patient-friendly dosing regimen when contrasted with traditional intravenous treatments, thereby positioning it as a potentially transformative alternative for individuals suffering from this severe ailment.
Who Are The Prominent Global Companies Shaping The Hereditary Transthyretin Amyloidosis Market Landscape?
Major companies operating in the hereditary transthyretin amyloidosis market are Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Pfizer Inc., Eli Lilly and Company, Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb, Merck and Co Inc., Johnson and Johnson, AbbVie Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Amgen Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Hereditary Transthyretin Amyloidosis Market During The Forecast Period?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Hereditary Transthyretin Amyloidosis Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2026, By The Business Research Company
Alzheimers Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Atrophic Glossitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report
Progressive Ataxia And Weakness Disorders Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model